Young people, their families and health professionals need access to trustworthy, evidence-based guidance to support decisions about health care. The National Health and Medical Research Council (NHMRC) is developing national clinical practice guidelines to support safe, appropriate and person-centred care for trans and gender diverse people aged under 18.
As part of this work, NHMRC has released the Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18 for public consultation. The Australian Government asked NHMRC to develop the national guidelines and identified advice on puberty suppressants as a priority.
What is recommended
The advice includes a conditional recommendation for the use of puberty suppressants for young people aged under 18 with gender incongruence.
As part of a shared decision between the young person, their parents or carers, and their clinicians, puberty suppressants can be considered for a young person who wants that care when the young person:
- has commenced puberty
- has gender incongruence, with or without distress
- is assessed as suitable for treatment in collaboration with clinicians.
A conditional recommendation recognises that treatment may be appropriate for some individuals but is not a one-size-fits-all decision. Shared decision-making involves young people, their parents or carers and clinicians discussing the available evidence, potential benefits and harms, and the young person's individual circumstances and preferences before deciding together whether treatment is appropriate.
NHMRC's Acting CEO, Ms Prue Torrance, said the national clinical guidelines under development are intended to support careful, individualised clinical decision-making.
'Young people and their families should be able to have informed discussions with their healthcare professionals, supported by the best available evidence and clear, trustworthy clinical guidance.
'Puberty suppressants are one possible part of care, and decisions about their use need to be made through shared decision making that involves the individual young person, their parents or carers and clinicians.'
Evidence-based and transparent
The advice has been developed with NHMRC's multidisciplinary Gender Guidelines Development Committee and is supported by a systematic review of the evidence. The development process follows NHMRC's Standards for Guidelines and Guidelines for Guidelines, together with the internationally recognised GRADE approach.
NHMRC's guideline process is designed to combine systematic assessment of the available scientific evidence with expert judgement and the views of people affected by the guidelines. People with experience of accessing care as a young person, or as a parent or carer, have been involved in developing the advice.
NHMRC's Acting CEO said transparency about the evidence and the basis for recommendations was particularly important.
'This is a complex area of health care in which there are strongly held views. NHMRC's role is to assess the evidence rigorously and transparently, and to provide guidance that clinicians, young people and families can trust.
'Public consultation is an important part of that process. We want to hear from young people and families, clinicians, researchers, professional organisations and others with relevant experience or evidence.'
Public consultation
Public consultation opens at 1 pm AEDT on Monday 16 November 2026 and closes at 1 pm AEDT on Monday 18 January 2027.
NHMRC is inviting feedback on the evidence considered, its interpretation, the proposed recommendations and good practice statements, implementation considerations and other matters directly relevant to the advice.
The advice and its supporting material, including the evidence evaluation report, technical report and administrative report, are available through the NHMRC website, with the advice also available through MAGICapp.
Submissions should be made through NHMRC's Consultation Hub.
Feedback received through the current consultation will be considered, and incorporated as needed, into the broader and more comprehensive national clinical guidelines, which are still under development. The full guidelines will address other aspects of care, including the use of gender-affirming hormones and psychosocial support, as well as the use of puberty suppressants. The full guidelines are expected to be available in 2028.